Unicycive Therapeutics filings document the regulatory, financing, governance, and operating disclosures of a Nasdaq-listed clinical-stage biotechnology company focused on kidney disease therapies. Form 8-K reports furnish financial results and business updates, including disclosures related to oxylanthanum carbonate, NDA activity, manufacturing matters, and the company’s cash and capital resources.
The filing record also covers common stock registered on the Nasdaq Capital Market, emerging growth company status, at-the-market equity sales under a shelf registration statement, and board and executive-governance matters. Proxy materials document director elections, auditor ratification, stockholder voting mechanics, and annual meeting procedures, while other current reports address securities litigation risk tied to public statements about the OLC program.
Townsend John reported acquisition or exercise transactions in this Form 4 filing.
Unicycive Therapeutics CFO John Townsend received a grant of 169,500 restricted stock units (RSUs) tied to the company’s common stock. This is a stock-based compensation award, not an open-market share purchase or sale.
According to the footnote, 23,542 shares vest upon grant, and an additional 4,708 shares vest over 31 months beginning on June 1, 2026, as long as he continues to serve at the company. Following this award, Townsend is shown as directly holding 169,500 RSUs, aligning his compensation more closely with the company’s future stock performance.
Jermasek Douglas reported acquisition or exercise transactions in this Form 4 filing.
Unicycive Therapeutics EVP Douglas Jermasek received a grant of 169,500 restricted stock units payable in common stock. According to the award terms, 23,542 shares vest immediately on grant and 4,708 shares vest monthly over 31 months beginning on June 1, 2026, contingent on continued service.
Unicycive Therapeutics, Inc. entered into a second amendment to its sales agreement with Guggenheim Securities to expand its at-the-market common stock offering capacity to $150,000,000. The at-the-market program allows the company to sell shares of common stock from time to time.
On the same date, Unicycive filed a Shelf Registration Statement on Form S-3, including a sales agreement prospectus, to register up to $50,000,000 of common stock for sale under this at-the-market offering. The amendment itself is incorporated by reference as an exhibit.
Unicycive Therapeutics, Inc. is registering up to $150,000,000 of securities on a shelf registration, including up to $50,000,000 of common stock that may be sold under a Sales Agreement with Guggenheim Securities, LLC.
Subsequent to March 31, 2026, pursuant to the Sales Agreement, the Company sold 1,693,000 shares of common stock at an average price of $7.34 per share for net proceeds of approximately $11.2 million. Shares of common stock issued and outstanding were 27,393,027 as of June 5, 2026. The prospectus describes multiple distribution methods and states that specific terms for any offering will be provided in a prospectus supplement.
Separately, the Company disclosed regulatory progress for its oxylanthanum carbonate NDA: the FDA accepted a resubmission as a Class II complete response with a PDUFA target action date of June 29, 2026.
Gupta Shalabh K. reported acquisition or exercise transactions in this Form 4 filing.
Unicycive Therapeutics, Inc. reported that CEO Shalabh K. Gupta received a grant of 762,200 restricted stock units. These RSUs are payable solely in common stock and vest in three equal installments on each anniversary of the grant date over three years, conditioned on his continued service with the company. Following this grant, Gupta is reported as holding 762,200 RSUs tied to an equal number of underlying common shares.
Kenkare-Mitra Sara reported acquisition or exercise transactions in this Form 4 filing.
Unicycive Therapeutics director Sara Kenkare-Mitra received two equity awards in the form of restricted stock units. On May 14, 2026, she was granted 42,100 RSUs that vest in three equal annual installments and 84,200 RSUs that vest after one year, all settling in common stock and tied to continued service with the company. Following these grants, she holds 126,300 RSUs directly as part of her compensation, with no open-market share purchases or sales reported.
Jermasek Douglas reported acquisition or exercise transactions in this Form 4 filing.
Unicycive Therapeutics, Inc. reported that EVP of Corporate Strategy Douglas Jermasek received a grant of 169,500 restricted stock units (RSUs) payable solely in common stock.
The RSU award vests in three equal installments, with 1/3 vesting on each anniversary of the grant date over three years, contingent on his continued service with the company. Following this grant, he is reported as holding 169,500 underlying shares tied to this RSU award.
Gupta Pramod reported acquisition or exercise transactions in this Form 4 filing.
Unicycive Therapeutics EVP Pramod Gupta received a grant of 169,500 restricted stock units (RSUs) payable in common stock. This equity award was granted at no cash cost to him and represents stock-based compensation rather than an open-market share purchase or sale.
According to the footnote, the RSU award vests in three equal parts: one-third on each anniversary of the grant date over three years, as long as Gupta continues his service with the company. Following this grant, he holds 169,500 RSUs directly, aligning his compensation more closely with Unicycive’s future share performance.
Unicycive Therapeutics, Inc. reported that CFO John Townsend received a grant of 169,500 restricted stock units as equity compensation. These RSUs are payable solely in common stock and carry no cash exercise price.
The RSU award vests in three equal installments, with one-third of the shares vesting on each anniversary of the grant date over three years, conditioned on Townsend’s continued service with the company. Following this grant, he holds 169,500 derivative securities linked to common stock, aligning part of his compensation with future share performance.
Laumas Sandeep reported acquisition or exercise transactions in this Form 4 filing.
Unicycive Therapeutics director Sandeep Laumas received two restricted stock unit grants as equity compensation. One RSU award covers 42,100 underlying shares of common stock and will vest in three equal annual installments starting on the first anniversary of the grant date, contingent on continued service.
The second, annual RSU award covers 84,200 underlying shares of common stock and will vest in full one year after the grant date, also subject to his continued service with the company. Following these grants, his reported direct RSU holdings tied to these awards total 126,300 and 84,200 units, respectively.